Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Endo/Women's Health TPX > Endo/Women's Health All > Flashcards

Endo/Women's Health All Flashcards

(66 cards)

Start Studying
1
Q

ADA standards of DM care in 2021
A1c
Pre-prandial glucose
Peak post-prandial glucose

A

A1c < 7%
Preprandial glucose 80-130mg/dL
Peak post prandial is <180mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Metformin Efficacy

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metformin Hypoglycemia

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metformin Weight Loss

A

Neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metformin CV Effects

A

ASCVD potential benefit

CHF neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Metformin Cost

A

Low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Metformin PO/SQ

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metformin CKD effects

A

Neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metformin renal dosing

A

contra in eGFR <30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metformin pearls

A

GI ADE common

VB12 deficiency common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

SGLT2i Rx names

A

Canagliflozin
Empagliflozin
Ertugliflozin
Dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SGLT2i Efficacy

A

Intermediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SGLT2i Hypoglycemia

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SGLT2i Weight Loss

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SGLT2i CV effects

A

ASCVD benefit: canagliflozin and empagliflozin

CHF benefit: canagliflozin, empagliflozin, dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

SGLT2i Cost

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

SGLT2i PO/SQ

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SGLT2i CKD effects

A

benefits: canagliflozin, empagliflozin, dapagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SGLT2i dosing

A

Canagliflozin - contra eGFR < 45
Empagliflozin - contra eGFR <30
Ertugliflozin - contra eGFR < 30
Dapagliflozin - contra eGFR <30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

SGLT2i pearls

A 
D/C rx before any surgery to avoid DKA
DKA risk is rare in T2DM
risk of bone fractures with canagliflozin
genitourinary infections
rick of vol depletion
increase in LDL
risk of Fournier's gangrene
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

GLP1 RAs Rx

A 
Exenatide
Liraglutide
Lixisenatide
Semaglutide SQ
Semaglutide PO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

GLP1 RAs Efficacy

A

High

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

GLP1 hypo

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

GLP1 Weight Loss

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
GLP1 CV effects
ASCVD benefit - Dulaglutide, Liraglutide, Semaglutide | CHF neutral
26
GLP1 costs
high
27
GLP1 SQ/PO
SQ and PO
28
GLP1 CKD effects
benefits on renal nd points in CVOTs, driven by albuminuria outcomes: liraglutide, semaglutide, dulaglutide
29
GLP1 Renal dosing
Exenatide and lixisenatide - avoid in eGFR <30 | no dosing adjustment in dulaglutide, liraglutide, or semaglutide
30
GLP1 Pearls
BBW -- risk of Thyroid C-cell tumors (all except lixisenatide) GI ADE common Inj site reactions may have acute pancreatitis risk
31
DPP4i Efficacy
intermediate
32
DPP4i hypo
No
33
DPP4 weight loss
Neutral
34
DPP4 CVD effects
ASCVD neutral | CHF potential risk: saxagliptin
35
DPP4 costs
High
36
DPP4 SQ/PO
PO
37
DPP4 CKD effects
Neutral
38
DPP4 renal dosing
Adjustment all required except for linagliptin
39
DPP4 pearls
Risk of acute pancreatitis | Joint pain
40
Thiazolidindiones (TZD) efficacy
High
41
TZD hypo
No
42
TZD weight loss
No, weight gain instead
43
TZD CV effects
ASCVD potential benefit - pioglitazone | CHF increased risk
44
TZD costs
Low
45
TZD PO/SQ
PO
46
TZD CKD effects
Neutral
47
TZD renal dosing
Not required, risk of fluid retention with renal impairment
48
TZD Pearls
FDA BBW - CHF risk Edema (fluid retention) Risk of bone fractures Risk of bladder CA (pio)
49
Sulfonylureas (SU) efficacy
High
50
SU hypo?
Yes
51
SU weight loss
No, weight gain
52
SU CV effects
ASCVD and CHF are neutral
53
SU costs
Low
54
SU PO/SQ
PO
55
SU CKD effects
Neutral
56
SU renal dosing
Glyburide - DO.NOT.USE Glipizide and glimepiride - start low and slow to avoid hypo
57
insulin 2 forms
Human and analog
58
Insulin efficacy
High
59
Insulin hypo
Yes
60
Insulin weight loss
No, gain
61
Insulin cv effects
ASCVD and CHF effects - neutral
62
Insulin costs
High
63
Insulin PO/SQ
SQ
64
Insulin CKD effects
Neutral
65
Insulin Renal dosing
Lower insulin doses with renal impairment | Titration based on clinical reponse
66
Insulin pearls
Injection site reactions | Hypo risk is less with analogs

Endo/Women's Health TPX (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions